Vol. 20/No.5 | OncologyLive

The Debate Over Early Screening for Pancreatic Cancer Continues

March 08, 2019

Higher costs associated with advanced stage pancreatic cancer, are potentially avoidable with screening and earlier treatment. However, the US Preventive Services Task Force in an ongoing draft review has reaffirmed its stance against screening in asymptomatic individuals.

Practical Treatment Questions Surface in HR-Positive Metastatic Breast Cancer

March 07, 2019

Novel and emerging agents are creating exciting new options for patients with hormone receptor–positive metastatic breast cancer, resulting in the need to consider how best to introduce and sequence these agents into the treatment timeline.

Panel Proposes Standards for Reporting Data From Immuno-Oncology Trials

March 06, 2019

The standards for reporting findings from immunotherapy studies should reflect the unique efficacy and toxicity characteristics of this rapidily emerging modality, with detailed and transparent explanations of definitions.

BCL-2 Emerges as an Attractive Target in Solid and Hematologic Cancers

March 06, 2019

Based on the crucial role of BCL-2 family proteins in apoptosis regulation, targeting these proteins using BCL-2 inhibitors offers a potentially new therapeutic option for patients with various types of hematologic malignancies and, more recently, patients with solid tumors.

Tumor Marker Trial Aims to Ease "Scanxiety" in Breast Cancer

March 05, 2019

Breast surveillance is essential when determining whether or not therapy is beneficial and to avoid toxicity, usual care for patients with metastatic breast cancer includes monitoring of symptoms and cancer burden.

New Targeted Therapy Duo Provides Advantages in BRAF-Mutant Melanoma

March 04, 2019

Keith T. Flaherty, MD, discussed the distinguishing features of the combination of encorafenib with binimetinib as well as some next steps, including the question of whether the regimen eventually could move to the adjuvant setting.

Stereotactic Body Radiotherapy Shows Potential in Oligometastatic Cancer

March 01, 2019

An increasing amount of evidence shows that a proportion of patients with cancer found to have low-volume metastases at diagnosis see meaningful benefit from aggressive local therapy. Equally important, there have been no meaningful reductions in reported quality of life among patients receiving intensive local therapy, and a small percentage of patients appear to be cured with this strategy.